{"title":"厄贝沙坦治疗心血管疾病的临床、药理特点及地位","authors":"E. V. Rebrova, E. Shikh, A.Yu. Ryazanovа","doi":"10.32756/0869-5490-2022-2-57-62","DOIUrl":null,"url":null,"abstract":"Irbesartan belongs to a group of angiotensin II receptor blockers that are used worldwide for the treatment of patients with hypertension, type 2 diabetes, and impaired renal function. Irbesartan can be administered alone or in combination with other antihypertensive drugs (for example, hydrochlorothiazide), if blood pressure control cannot be achieved with monotherapy. The mechanism of action of Irbesartan is mainly due to the selective blockade of AT1 receptors and, as a consequence, a decrease in the vasopressor effect of angiotensin II. The review article summarizes pharmacokinetic and pharmacodynamic properties and clinical data on the tolerability and safety of Irbesartan.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"261 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical and pharmacological features and place of irbesartan in the treatment of cardiovascular diseases\",\"authors\":\"E. V. Rebrova, E. Shikh, A.Yu. Ryazanovа\",\"doi\":\"10.32756/0869-5490-2022-2-57-62\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Irbesartan belongs to a group of angiotensin II receptor blockers that are used worldwide for the treatment of patients with hypertension, type 2 diabetes, and impaired renal function. Irbesartan can be administered alone or in combination with other antihypertensive drugs (for example, hydrochlorothiazide), if blood pressure control cannot be achieved with monotherapy. The mechanism of action of Irbesartan is mainly due to the selective blockade of AT1 receptors and, as a consequence, a decrease in the vasopressor effect of angiotensin II. The review article summarizes pharmacokinetic and pharmacodynamic properties and clinical data on the tolerability and safety of Irbesartan.\",\"PeriodicalId\":10353,\"journal\":{\"name\":\"Clinical pharmacology and therapy\",\"volume\":\"261 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical pharmacology and therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32756/0869-5490-2022-2-57-62\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical pharmacology and therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32756/0869-5490-2022-2-57-62","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Clinical and pharmacological features and place of irbesartan in the treatment of cardiovascular diseases
Irbesartan belongs to a group of angiotensin II receptor blockers that are used worldwide for the treatment of patients with hypertension, type 2 diabetes, and impaired renal function. Irbesartan can be administered alone or in combination with other antihypertensive drugs (for example, hydrochlorothiazide), if blood pressure control cannot be achieved with monotherapy. The mechanism of action of Irbesartan is mainly due to the selective blockade of AT1 receptors and, as a consequence, a decrease in the vasopressor effect of angiotensin II. The review article summarizes pharmacokinetic and pharmacodynamic properties and clinical data on the tolerability and safety of Irbesartan.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
